Indoco Remedies Ltd. released an investor presentation detailing its unaudited financial results for the quarter and half-year ended September 30, 2024, highlighting a 13% revenue CAGR and a PAT CAGR of 8% over three years, with a credit rating of AA- for long-term borrowings.